| 000 | 01524 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517131733.0 | ||
| 264 | 0 | _c20171214 | |
| 008 | 201712s 0 0 eng d | ||
| 022 | _a1473-656X | ||
| 024 | 7 |
_a10.1097/GCO.0000000000000333 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBayer, Christian M | |
| 245 | 0 | 0 |
_aUpdates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment. _h[electronic resource] |
| 260 |
_bCurrent opinion in obstetrics & gynecology _c02 2017 |
||
| 300 |
_a4-11 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xpharmacology |
| 650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aBone and Bones _xdrug effects |
| 650 | 0 | 4 |
_aBreast Neoplasms _xgenetics |
| 650 | 0 | 4 | _aChemoprevention |
| 650 | 0 | 4 |
_aDenosumab _xpharmacology |
| 650 | 0 | 4 |
_aDiphosphonates _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGenes, BRCA1 _xphysiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aOsteoprotegerin _xmetabolism |
| 650 | 0 | 4 |
_aRANK Ligand _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReceptor Activator of Nuclear Factor-kappa B _xmetabolism |
| 650 | 0 | 4 | _aRisk |
| 700 | 1 | _aBeckmann, Matthias W | |
| 700 | 1 | _aFasching, Peter A | |
| 773 | 0 |
_tCurrent opinion in obstetrics & gynecology _gvol. 29 _gno. 1 _gp. 4-11 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/GCO.0000000000000333 _zAvailable from publisher's website |
| 999 |
_c26720022 _d26720022 |
||